Protalix BioTherapeutics Q3 EPS $(0.04), Inline, Sales $10.35M Beat $10.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Protalix BioTherapeutics reported Q3 losses of $(0.04) per share, in line with analyst consensus. This is a 42.86% increase over losses from the same period last year. The company's quarterly sales of $10.35M beat the analyst consensus estimate of $10.00M by 3.45%, but this is a 27.06% decrease over sales from the same period last year.
November 06, 2023 | 11:52 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Protalix BioTherapeutics reported Q3 earnings in line with estimates but showed a decrease in sales compared to the same period last year.
Protalix BioTherapeutics' Q3 earnings were in line with analyst expectations, which is generally a positive sign. However, the company's sales decreased compared to the same period last year, which could be a concern for investors. The net impact on the stock is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100